United BioSource Corporation is pleased to introduce Bracket, a Specialty Services provider dedicated to helping pharmaceutical sponsors and contract research organizations (CROs) achieve greater certainty and accurate outcomes in their clinical trials. Bracket combines two existing UBC businesses: UBC's Clinical Technologies Group and Specialty Clinical Services business. The company's goal in operating these formerly distinct business units as one cohesive business is to leverage the integration of science, technology and operational excellence and expand our portfolio of specialty products so they can best help customers optimize their research and development activities.
Bracket will continue to offer its pre-approval specialty solutions, including e-Clinical Technologies such as IVRS, ePRO, and eLearning as well as comprehensive Endpoint Reliability Solutions that incorporate Rater Training, Endpoint Adjudication, Ratings Surveillance, and Computerized Cognitive Testing.
The alignment of this breadth of capability is designed to address the new paradigm in clinical development: one that demands tools and analytics to optimize decision-making and ultimately provide greater precision. Although operating under a new and distinct public brand, Bracket will remain a UBC company.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.